Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | SLC10A1 | Q14973 | 9/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21868951 | 0.84 | ALDH1A1 (0.40) | ALDH1A1PTGS2PTGS1MAPK1MEN1 | |
| SCHEMBL21869103 | 0.81 | ALDH1A1 (0.37) | ALDH1A1MAPK1 | |
| SCHEMBL21869337 | 0.77 | SLC10A1 (0.33) | ALDH1A1PTGS2PTGS1SLC10A1MAPK1 | |
| SCHEMBL21869151 | 0.76 | SLC10A1 (0.52) | SLC10A1 | |
| SCHEMBL21868966 | 0.75 | SMARCA2 (0.42) | PTGS2PTGS1SLC10A1 | |
| SCHEMBL21869105 | 0.74 | SLC10A1 (0.35) | ALDH1A1PTGS2PTGS1SLC10A1KMT2A | |
| SCHEMBL21869178 | 0.74 | SCN10A (0.42) | SLC10A1 | |
| SCHEMBL22646287 | 0.73 | ALDH1A1 (0.36) | ALDH1A1PTGS2PTGS1SLC10A1MAPK1 | |
| SCHEMBL21868845 | 0.68 | MEN1 (0.36) | ALDH1A1PTGS2PTGS1SLC10A1MEN1 | |
| SCHEMBL24890429 | 0.65 | MAPK1 (0.38) | ALDH1A1SLC10A1MAPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591334-B2 | Substituted pyrrolizines for the treatment of hepatitis B | SHANGHAI LONGWOOD BIOPHARMACEUTICALS CO., LTD. (CN) | 2023-02-28 | — | — | US | disclosed |
| US-20200354366-A1 | BICYCLIC NUCLEOCAPSID INHIBITOR AND USE OF SAME AS DRUG IN TREATMENT OF HEPATITIS B | SHANGHAI LONGWOOD BIOPHARMACEUTICALS CO., LTD. (CN) | 2020-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591334-B2 | Substituted pyrrolizines for the treatment of hepatitis B | SLC10A1, NUP188, NR1H4 | ALDH1A1 2589/4885PTGS2 2334/4885PTGS1 970/4885 |
| US-20200354366-A1 | BICYCLIC NUCLEOCAPSID INHIBITOR AND USE OF SAME AS DRUG IN TREATMENT OF HEPATITIS B | SLC10A1, NR1H4, NUP188 | ALDH1A1 3164/4885PTGS2 3420/4885PTGS1 2835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.